Revolution Medicines
RVMD · Nasdaq · United States
Share price · RVMD
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when RVMD's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 11 Nov 2026-6.4%
Nothing announced by RVMD that day or the session before.
- 6 Nov 2026+8.2%
Nothing announced by RVMD that day or the session before.
- 8 Oct 2026-6.3%
Nothing announced by RVMD that day or the session before.
- 24 Sep 2026+4.8%
Nothing announced by RVMD that day or the session before.
- 16 Sep 2026-4.4%
Nothing announced by RVMD that day or the session before.
- 28 Apr 2026+10.0%
Nothing announced by RVMD that day or the session before.
- 13 Apr 2026+41.3%
- 26 Jan 2026-16.9%
Nothing announced by RVMD that day or the session before.
- 9 Jan 2026+10.5%
- 7 Jan 2026+28.6%
Nothing announced by RVMD that day or the session before.
Share of unusual movement by asset
For each asset, the share of RVMD's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(5 total)
| Target & Modality | |||
|---|---|---|---|
Daraxonrasib(Rasonque) | Approved | pan-RAS · RAS (pan-RAS, RAS-mutant tumors)Small molecule | Non-Small Cell Lung CancerPancreatic Ductal Adenocarcinoma |
| Phase 3 | KRAS G12DSmall molecule | Non-Small Cell Lung CancerPancreatic Cancer | |
| Phase 1/2 | KRAS G12CSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 1 | KRAS G12VSmall molecule | Non-Small Cell Lung Cancer | |
| Phase 1 | mTORC1 (mammalian target of rapamycin complex 1) (inhibitor)Small molecule | Non-Small Cell Lung Cancer |
Upcoming events
(11 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (3)
May 2027 (1)
What to watch
June 2027 (1)
What to watch
December 2027 (1)
What to watch
2028 (4)
April 2028 (1)
What to watch
September 2028 (1)
What to watch
December 2028 (2)
What to watch
What to watch
2029 (4)
March 2029 (1)
What to watch
May 2029 (2)
What to watch
What to watch
October 2029 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $198M | $417M | $616M+ $3.0B short-term inv. | $407M-$416M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $395M | $815M+ $3.1B short-term inv. | $644M-$387M operating cash flow | report ↗ |
| 2026-Q1 | — | $344M | $441M+ $1.5B short-term inv. | $454M-$354M operating cash flow | report ↗ |
| 2025-Q3 | — | $263M | $217M+ $1.7B short-term inv. | $305M-$207M operating cash flow | report ↗ |
| 2025-Q2 | — | $224M | $402M+ $1.7B short-term inv. | $248M-$222M operating cash flow | report ↗ |
| 2025-Q1 | — | $206M | $334M+ $1.8B short-term inv. | $213M-$194M operating cash flow | report ↗ |
| 2024-Q3 | $0 | $152M | $201M+ $1.3B short-term inv. | $156M-$130M operating cash flow | report ↗ |
| 2024-Q2 | $0 | $135M | $276M+ $1.3B short-term inv. | $133M-$128M operating cash flow | report ↗ |
| 2024-Q1 | $0 | $118M | $288M+ $1.4B short-term inv. | $116M-$161M operating cash flow | report ↗ |
| 2023-Q3 | $0 | $108M | $358M+ $455M short-term inv. | $108M-$101M operating cash flow | report ↗ |
| 2023-Q2 | $3.8M | $98M | $380M+ $529M short-term inv. | $98M-$67M operating cash flow | report ↗ |
| 2023-Q1 | $7.0M | $69M | $427M+ $483M short-term inv. | $68M-$62M operating cash flow | report ↗ |
| 2022-Q3 | $3.4M | $69M | $179M+ $476M short-term inv. | $73M-$52M operating cash flow | report ↗ |
| 2022-Q2 | $9.1M | $61M | $106M+ $356M short-term inv. | $61M-$56M operating cash flow | report ↗ |
| 2022-Q1 | $7.6M | $56M | $98M+ $421M short-term inv. | $58M-$55M operating cash flow | report ↗ |
| 2021-Q3 | $1.1M | $46M | $129M+ $480M short-term inv. | $53M-$37M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $0 | $987M | $384M+ $1.6B short-term inv. | $283M-$898M operating cash flow | report ↗ |
Revolution Medicines reported FY2025 revenue of $0M, flat YoY, with R&D expenses of $987.3M, up 66.7% YoY from $592.2M. Cash, cash equivalents and marketable securities were $2.0B as of December 31, 2025, including a $250M royalty monetization tranche received in June 2025. The company posted a full-year net loss of $1.1B versus $600.1M in 2024, and a fourth-quarter net loss of $364.9M versus $194.6M.
The company guided FY2026 GAAP operating expenses to $1.6B–$1.7B, including non-cash stock-based compensation of $180M–$200M. Clinically, it expects a RASolute 302 Phase 3 readout for daraxonrasib in second-line metastatic pancreatic cancer in the first half of 2026, expects to substantially complete enrollment in RASolve 301 in previously treated NSCLC this year, initiated RASolute 305 for zoldonrasib in first-line G12D-mutant pancreatic cancer, and plans further Phase 3 starts including RASolute 309 and RASolve 308. It also dosed the first patient with RMC-5127, reported encouraging initial zoldonrasib plus FOLFIRINOX data, disclosed collaborations with Summit, Tango, and Bristol Myers Squibb, and received FDA Breakthrough Therapy designation for zoldonrasib.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $0 | $592M | $543M+ $1.7B short-term inv. | $150M-$557M operating cash flow | report ↗ |
| 2023-FY | $12M | $423M | $696M+ $1.2B short-term inv. | $109M-$351M operating cash flow | report ↗ |
| 2022-FY | $35M | $253M | $161M+ $484M short-term inv. | $62M-$224M operating cash flow | report ↗ |
| 2021-FY | $29M | $187M | $109M+ $469M short-term inv. | $47M-$147M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 172 sales ($159.6M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-11-16 | Kelsey Stephen Michael · See Remarks | Option exercise | 27,160 | $18.56 | $504K | Form 4 |
| 2026-11-16 | Kelsey Stephen Michael · See Remarks | Open-market sale | 11,542 | $166.75 | $1.9M | Form 4 |
| 2026-11-16 | Kelsey Stephen Michael · See Remarks | Open-market sale | 3,627 | $167.66 | $608K | Form 4 |
| 2026-11-16 | Kelsey Stephen Michael · See Remarks | Open-market sale | 8,039 | $168.64 | $1.4M | Form 4 |
| 2026-11-16 | Kelsey Stephen Michael · See Remarks | Open-market sale | 3,052 | $169.46 | $517K | Form 4 |
| 2026-11-16 | Kelsey Stephen Michael · See Remarks | Open-market sale | 700 | $170.40 | $119K | Form 4 |
| 2026-11-16 | Kelsey Stephen Michael · See Remarks | Open-market sale | 200 | $171.65 | $34K | Form 4 |
| 2026-11-16 | Kelsey Stephen Michael · See Remarks | Option exercise (derivative) | 27,160 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 508 reporting institutions held 198.5M shares ($18.6B, 91.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | FARALLON CAPITAL MANAGEMENT LLC | 13,604,796 | $1.3B |
| 2 | BlackRock, Inc. | 11,212,706 | $1.1B |
| 3 | JANUS HENDERSON GROUP PLC | 9,766,496 | $949.5M |
| 4 | BAKER BROS. ADVISORS LP | 9,555,357 | $929.3M |
| 5 | FMR LLC | 8,464,314 | $823.2M |
| 6 | VANGUARD CAPITAL MANAGEMENT LLC | 8,362,284 | $813.2M |
| 7 | Nextech Invest, Ltd. | 7,601,087 | $739.2M |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 7,502,623 | $729.6M |
| 9 | Paradigm Biocapital Advisors LP | 6,655,703 | $647.3M |
| 10 | WELLINGTON MANAGEMENT GROUP LLP | 6,027,819 | $586.2M |
| 11 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 5,475,611 | $532.5M |
| 12 | STATE STREET CORP | 4,402,662 | $428.2M |
| 13 | UBS Group AG | 4,386,791 | $426.6M |
| 14 | GEODE CAPITAL MANAGEMENT, LLC | 3,338,142 | $323.9M |
| 15 | Alphabet Inc. | 3,292,525 | $320.2M |